Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT ID
NCT04751396
Registry status
Recruiting
Study type
Observational
Sponsor
M.D. Anderson Cancer Center
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis

Overview

ClinicalTrials.gov lists this study as Recruiting.

Official title: Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers

Enrollment: 125 participants (Estimated).

What is being studied

  • Other: Best Practice
  • Intervention: Child Health Services
  • Intervention: Community Health Services
  • Intervention: Data Collection
  • Intervention: Early Intervention, Educational
  • Other: Educational Intervention
  • Intervention: Educational Status
  • Intervention: Environment and Public Health
  • Intervention: Epidemiologic Methods
  • Intervention: Guidelines as Topic
  • Intervention: Health Care Evaluation Mechanisms
  • Intervention: Health Care Facilities Workforce and Services
  • Intervention: Health Care Quality, Access, and Evaluation
  • Intervention: Health Services
  • Intervention: Health Services Administration
  • Other: Interview
  • Intervention: Interviews as Topic
  • Intervention: Investigative Techniques
  • Intervention: Methods
  • Intervention: Population Characteristics
  • Intervention: Practice Guidelines as Topic
  • Intervention: Preventive Health Services
  • Intervention: Public Health
  • Intervention: Quality Assurance, Health Care
  • Intervention: Quality Indicators, Health Care
  • Intervention: Quality of Health Care
  • Other: Questionnaire Administration
  • Intervention: Socioeconomic Factors
  • Intervention: Standard of Care
  • Other: Survey Administration

Who may be eligible

Ages
18 Years to no maximum
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Diagnosis of melanoma * Diagnosis of pre-existing autoimmune disease * Inflammatory bowel disease * Diagnosis of Crohn's disease or ulcerative colitis by a gastroenterologist * For ulcerative colitis, proof of chronic changes over time (i.e., 6 months) and signs of inflammation histologically * Treatment with aminosalicylates, corticosteroids, thiopurines, or immune modifiers (e.g., calcineurin inhibitors, methotrexate, adhesion molecule antagonists) * Rheumatoid arthritis * Diagnosis of rheumatoid arthritis by a rheumatologist * Treatment with traditional disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, hydroxychloroquine) or targeted therapy * Systemic lupus erythematosus * Diagnosis of systemic lupus erythematosus by a rheumatologist * Psoriasis * Diagnosis of psoriasis by a dermatologist * Treatment with corticosteroids, vitamin D analogs, anthralin, topical retinoids, calcineurin inhibitors, salicylic acid, coal tar, or moisturizers; light therapy, including sunlight, ultraviolet B (UVB) phototherapy, narrowband UVB therapy, Goeckerman therapy, photochemotherapy, excimer laser, or pulsed dye laser; or systemic medications, including retinoids, methotrexate, cyclosporine, hydroxyurea, or thioguanine or targeted therapies * Spondyloarthropathies * Diagnosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis, or enteropathic arthritis/spondylitis by a rheumatologist * Treatment with disease-modifying antirheumatic drugs (e.g., sulfasalazine) or targeted therapy * Age of 18 years or older * Patients whose physicians had recommended they begin using any of the currently available immune checkpoint inhibitors or people who are in the midst of or have already made the decision on whether or not start an immune checkpoint inhibitor * E-mail access and computer with Internet access or telephone * Ability to communicate in English or Spanish * CLINICIAN * Prescribed immune checkpoint inhibitors * Are providing care for patients with melanoma * In the clinics at MD Anderson

Study locations

1 study location is listed.

Recruiting site status is explicitly provided for 1 location; 1 is listed as Recruiting.

Countries: United States

  • Texas, United States: 1

Sample of listed locations

  • M D Anderson Cancer Center — Houston, Texas, 77030, United States — Recruiting

Study details

Start date
April 20, 2022
Primary completion date
February 2, 2027
Completion date
February 2, 2027
First posted
February 12, 2021
Collaborators
National Cancer Institute (NCI)

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT04751396
Registry last updated
May 20, 2026
QualifiedStudies registry data refreshed
October 2, 2026
QualifiedStudies record fetched
October 2, 2026

View NCT04751396 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Clinical trial FAQ